Atlas Trials

Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis

Clinical trial NCT06106672 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT06106672
Sponsor
COUR Pharmaceutical Development Company, Inc.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Myasthenia GravisGeneralized MyastheniaAChR Myasthenia GravisMuSK MG
Start date
2024-05-30
Primary completion
2026-06-01
Enrollment
54

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.